Clinical Trials Logo

Clinical Trial Summary

Hypothesis : pegfilgrastim at 200 µg/kg between 12 and 18 days after previous chemotherapy provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed


Clinical Trial Description

Patients: consecutively referred for HSC mobilization. 12 to 18 days after the previous chemotherapy. No haematological growth factor during the 8 previous days.

Mobilization: one sc injection of 200 µg/kg pegfilgrastim (Neulasta, Amgen) Evaluation during the study: CD34 circulating cells from day 3 to day 7 ; AE recording Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 3 blood volume processed) Analysis: sequential Bayesian study ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00751894
Study type Interventional
Source University Hospital, Clermont-Ferrand
Contact Patrick Lacarin
Phone 04.73.75.11.95
Email placarin@chu-clermontferrand.fr
Status Not yet recruiting
Phase Phase 2

See also
  Status Clinical Trial Phase
Completed NCT01202370 - A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1
Completed NCT00162136 - Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. Phase 1
Recruiting NCT05006794 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Phase 1
Active, not recruiting NCT02537418 - Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens Phase 1
Completed NCT01540526 - Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Phase 1
Completed NCT00033202 - This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor Phase 1
Recruiting NCT04492735 - The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Completed NCT05866354 - To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies Phase 1
Completed NCT02640755 - Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase Phase 1
Terminated NCT00695370 - Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children Phase 2
Completed NCT02325739 - FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression Phase 1/Phase 2
Completed NCT00676299 - A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. Phase 1
Active, not recruiting NCT00090727 - Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Phase 1
Terminated NCT01112397 - Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours Phase 1